Recruiting
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
NCT07022678· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Recruiting
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
NCT07466316· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662· Phase 2· National Cancer Institute (NCI)· Source
Contact: Michael J. Ferguson (principal investigator)
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157· Phase 2· National Cancer Institute (NCI)· Source
Contact: Michael J. Ferguson (principal investigator)
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Recruiting
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
NCT06647953· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Trauma-Informed Procedural Pain Intervention: Refinement of an Evidence-Based Protocol
NCT06705491· University of Louisville· Source
Active, not recruiting
Left Ventricular Impella Device Real-World Evaluation in Pediatric Patients
NCT07943182· Abiomed Inc.· Source
Recruiting
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082· Phase 3· Novartis Pharmaceuticals· Source
Contact: Meagan Despain
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817· Phase 2· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Recruiting
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
NCT05711667· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· Phase 3· National Cancer Institute (NCI)· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· Phase 3· Children's Oncology Group· Source
Active, not recruiting
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
NCT04203316· Phase 2· Children's Oncology Group· Source
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· Phase 3· National Cancer Institute (NCI)· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
NCT05457556· Phase 3· Children's Oncology Group· Source
Active, not recruiting
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source
Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT05382338· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035· Phase 3· PedAL BCU, LLC· Source
Recruiting
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
NCT05099003· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
NCT04939597· Phase 3· Children's Oncology Group· Source
Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241· Phase 1/2· PedAL BCU, LLC· Source
Contact: Michael J. Ferguson (principal investigator)
Recruiting
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT05235165· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132· Phase 3· Children's Oncology Group· Source
Recruiting
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04684368· Phase 2· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT04315324· Phase 1/2· SWOG Cancer Research Network· Source
Active, not recruiting
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
NCT04385277· Phase 2· Children's Oncology Group· Source
Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· Phase 2· National Cancer Institute (NCI)· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
NCT04089358· Phase 3· Children's Oncology Group· Source
Recruiting
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318· Phase 2· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04284774· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
NCT04195399· Phase 2· Children's Oncology Group· Source
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
NCT04258943· Phase 1/2· Children's Oncology Group· Source
Active, not recruiting
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
NCT03919071· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409· Phase 3· National Cancer Institute (NCI)· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT03871257· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
NCT03817398· Phase 2· Children's Oncology Group· Source
Recruiting
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085· Phase 3· Children's Oncology Group· Source
Contact: Michael J. Ferguson (principal investigator)
Active, not recruiting
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
NCT03834961· Phase 2· Children's Oncology Group· Source
Active, not recruiting
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT03794349· Phase 2· Children's Oncology Group· Source
Active, not recruiting
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
NCT03595124· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
NCT03581292· Phase 2· Children's Oncology Group· Source
Showing 50 of 72.